Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription (活血解毒方) in the treatment of polycythemia vera with heat toxin and blood stasis syndrome

doi:10.19852/j.cnki.jtcm.2025.06.014

Journal of Traditional Chinese Medicine ›› 2025, Vol. 45 ›› Issue (6): 1353-1365.DOI: 10.19852/j.cnki.jtcm.2025.06.014

• Original Articles • Previous Articles Next Articles

Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription (活血解毒方) in the treatment of polycythemia vera with heat toxin and blood stasis syndrome

ZHAO Yumin¹^,²^,³, ZHANG Yuliang⁴, WANG Guozi⁴, LIU Xizan⁴, ZHAO Pengmin⁴, ZHAO Mengjun⁴, LI Zhaoxia⁵, DI Haixia⁴

1 College of Graduate Studies, Hebei North University, Zhangjiakou 075000, China
2 4th Hematology Department, Langfang Hospital of Traditional Chinese Medicine, Langfang 065000 China
3 Medical Department, Second Hospital of Zhangjiakou, Zhangjiakou 075000, China
4 4th Hematology Department, Langfang Hospital of Traditional Chinese Medicine, Langfang 065000 China
5 College of Graduate Studies, Hebei North University, Zhangjiakou 075000, China

Received:2024-07-12 Accepted:2024-10-28 Online:2025-12-15 Published:2025-11-24
Contact: DI Haixia, 4th Hematology Department, Langfang Hospital of Traditional Chinese Medicine, Langfang 065000 China. dhx-55555@163.com, Telephone: +86-18031603706
Supported by:
Scientific Research Project of the Chinese Society of Ethnographic Medicine: A Feasibility Study on the Treatment of Polycythemia Vera with Stasis-Expelling Decoctions Based on the Theory of Activating Blood and Resolving Stasis(2020, 2020ZY175-440801);Scientific Research Project of the Chinese Society of Traditional Chinese Medicine: a Real-World Prospective Study on the Use of Stasis-Expelling Decoctions in Treating Polycythemia Vera(2021, 202169-003);National Administration of Traditional Chinese Medicine Yang Shulian’s National Famous Traditional Chinese Medicine Expert Inheritance Studio Construction Project (State Administration of Traditional Chinese Medicine Jiaohan [2022] No. 75);Hebei Province Graduate Innovation Funding Project(2023, PX-19221895);Beijing-Tianjin-Hebei Traditional Chinese Medicine Collaborative Specialty Alliance (Hebei Traditional Chinese Medicine [2024] No. 11)

1. .pdf(1018KB)

Abstract

Abstract:

OBJECTIVE: To explore the clinical efficacy and potential mechanisms of Huoxue Jiedu prescription (活血解毒方) in the treatment of polycythemia vera and provide objective basis for the treatment of polycythemia vera by using network pharmacology, molecular docking technology, and clinical trials.

METHODS: First, network pharmacology and molecular docking analysis methods were used to screen the main targets of Huoxue Jiedu prescription in the treatment of polycythemia vera. Patients who were first diagnosed with polycythemia vera in the Hematology Department of Langfang Hospital of Traditional Chinese Medicine from September 2022 to January 2024 were enrolled, and a clinical randomized controlled study was conducted. Sixty patients with primary polycythemia who met the inclusion criteria were randomly divided into the treatment group and the control group, with 30 cases in each group. The control group received oral Western Medicine treatment, whereas the treatment group received oral Western Medicine combined with Huoxue Jiedu prescription treatment, and three courses were observed. The differences in the efficacy of Traditional Chinese and Western Medicine, hematological indicators, coagulation function, and expression of related targets before and after treatment were observed between the two groups. SPSS 26.0 statistical software was used for data analysis, and the treatment results of the two groups were compared to observe their clinical efficacy and mechanisms.

RESULTS: Network pharmacology results identified the phosphatidyqinositol-3 kinase (PI3K-Akt) pathway as an important pathway of Huoxue Jiedu prescription in the treatment of polycythemia veraPV, which was closely related to thrombosis. Clinical trial results showed that Huoxue Jiedu prescription improved efficacy and hematological indicators, reduced patients’ coagulation indicators such as D-dimer and fibrinogen, reduced activated partial thromboplastin time and prothrombin time, and decreased the expression of PI3K and Serine/threonine-protein kinase AKT1 (AKT1) mRNA in peripheral blood.

CONCLUSION: Network pharmacology predicted the corresponding targets of traditional Chinese medicine to a certain extent. Huoxue Jiedu prescription could enhance clinical efficacy, improve hematological indicators, and reduce coagulation indicators through antithrombotic effect by inhibiting the expression of PI3K and AKT1.

Key words: polycythemia vera, network pharmacology, molecular docking, thrombosis

ZHAO Yumin, ZHANG Yuliang, WANG Guozi, LIU Xizan, ZHAO Pengmin, ZHAO Mengjun, LI Zhaoxia, DI Haixia. Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription (活血解毒方) in the treatment of polycythemia vera with heat toxin and blood stasis syndrome[J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1353-1365.

Figures/Tables 12

References 38.

1.	Anderson LA, McMullin MF. Epidemiology of MPN: what do we know? Curr Hematol Malig Rep 2014; 9: 340-9. DOI URL
2.	Titmarsh GJ, Duncombe AS, McMullin MF, et al. How common are myeloproliferative neoplasms? A systematic review and Meta-analysis. Am J Hematol 2014; 89: 581-7. PMID
3.	Tefferi A, Rumi E, Finazzi G, et al. Survival and prognosis among 1545 patients with contemporary polycythemia vera: an international study. Leukemia 2013; 27: 1874-81. DOI PMID
4.	Wehmeier A, Daum I, Jamin H, et al. Incidence and clinical risk factors for bleeding and thrombotic complications in myeloproliferative disorders. a retrospective analysis of 260 patients. Ann Hematol 1991; 63: 101- 6. PMID
5.	Berk PD, Goldberg JD, Donovan PB, et al. Therapeutic recommendations in polycythemia vera based on Polycythemia Vera Study Group protocols. Semin Hematol 1986; 23: 132-43. PMID
6.	Steinhubl SR, Bhatt DL, Brennan DM, et al. Aspirin to prevent cardiovascular disease: the association of aspirin dose and clopidogrel with thrombosis and bleeding. Ann Intern Med 2009; 150: 379- 86. DOI PMID
7.	Hankey GJ, Eikelboom JW. Aspirin resistance. Lancet 2006; 367: 606-17. PMID
8.	Davì G, Patrono C. Platelet activation and atherothrombosis. N Engl J Med 2007; 357: 2482-94.
9.	Su SB, Lu A, Li S, Jia W. Evidence-Based ZHENG: a Traditional Chinese Medicine syndrome. Evid Based Complement Alternat Med 2012; 2012: 246538.
10.	Yu H, Chen J, Xu X, et al. A systematic prediction of multiple drug-target interactions from chemical, genomic, and pharmacological data. PLoS One 2012; 7: e37608.
11.	Burley SK, Bhikadiya C, Bi C, et al. RCSB Protein Data Bank: powerful new tools for exploring 3D structures of biological macromolecules for basic and applied research and education in fundamental biology, biomedicine, biotechnology, bioengineering and energy sciences. Nucleic Acids Res 2021; 49: D437-51. DOI PMID
12.	Leukemia and Lymphoma Group of the Hematology Branch of the Chinese Medical Association. Chinese guidelines for diagnosis and treatment of polycythemia vera (2022 Edition). Zhong Hua Xue Ye Xue Za Zhi 2022; 43: 537-41.
13.	Di HX, Liu XZ, Wang GZ, Zhang YL, Li YZ. Expert consensus on the diagnosis and treatment of polycythemia vera using integrated Traditional Chinese and Western Medicine (2022). Zhong Guo Zhong Xi Yi Jie He Za Zhi 2023; 43: 1-7.
14.	Barosi G, Mesa R, Finazzi G, et al. Revised response criteria for polycythemia Vera and essential thrombocythemia: an ELN and IWG-MRT consensus project. Blood 2013; 121: 4778-81. DOI PMID
15.	Zheng X. Guiding principles for clinical research of new Chinese medicines (Trial). Beijing: China Medical Science and Technology Press, 2002: 263-8.
16.	Etti I, Abdullah R, Hashim NM, et al. Artonin E and structural Analogs from Artocarpus species abrogates estrogen receptor signaling in breast cancer. Molecules 2016; 21: 839.
17.	Zhang N, Wang Y, An L, et al. Entropy drives the formation of salt bridges in the Protein GB3. Angew Chem Int Ed Engl 2017; 56: 7601-4. DOI URL
18.	Wang WL, Wang WN, Wang SF, et al. "Schrödinger Equation-Approximate Models-Core Concepts-Simple Applications”: constructing a logical framework and knowledge graph of atom and molecule structures. Da Xue Hua Xue 2024; 39: 338-43.
19.	Arunan E, Mani D. Dynamics of the chemical bond: inter- and intra-molecular hydrogen bond. Faraday Discuss 2015; 177: 51-64. DOI PMID
20.	Dai C, Chung IJ, Krantz SB. Increased erythropoiesis in polycythemia vera is associated with increased erythroid progenitor proliferation and increased phosphorylation of Akt/PKB. Exp Hematol 2005; 33: 152-8. DOI PMID
21.	Liu Y, Yin HJ, Chen KJ. Effect of paeoniflorin and ligustrazine on the F-actin-induced platelet activation level and platelet gelsolin in vitro. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2020; 40: 313-7.
22.	Zhang K, Ma X, Han SY, et al. Ameliorative effect of Panax ginseng saponins combined with Salvia miltiorrhiza phenolic acids on hemorheological abnormality in rats with acute blood stasis. Zhong Guo Yao Li Xue Yu Du Li Xue Za Zhi 2012; 26: 641-5.
23.	Wang MM, Xue M, Xu YG, et al. Panax notoginseng saponin is superior to aspirin in inhibiting platelet adhesion to injured endothelial cells through COX pathway in vitro. Thromb Res 2016; 141: 146-52. DOI URL
24.	Wang ZY, Wang X, Zhang DY, Hu YJ, Li S. Traditional Chinese Medicine network pharmacology: development in new era under guidance of network pharmacology evaluation method guidance. Zhong Guo Zhong Yao Za Zhi 2022; 47: 7-17.
25.	Ding J, Shanshan M, Mengcheng C, Danying Z, Jin Y. Integrated network pharmacology and clinical study to reveal the effects and mechanisms of Bushen Huoxue Huatan decoction on polycystic ovary syndrome. Evid Based Complement Alternat Med 2022; 2022: 2635375.
26.	Zhang P, Zhang D, Zhou W, et al. Network pharmacology: towards the artificial intelligence-based precision Traditional Chinese Medicine. Brief Bioinform 2023; 25: bbad518.
27.	Li S, Zhang B. Traditional Chinese Medicine network pharmacology: theory, methodology and application. Chin J Nat Med 2013; 11: 110-20. DOI URL
28.	Wu DY, Deng Y, Hao J, Xu X. PI3K/AKT/mTORsignaling mediates baicalin-inhibited proliferation in hypertrophic scar fibroblast. Zhong Guo Sheng Wu Hua Xue Yu Fen Zi Sheng Wu Xue Bao 2014; 30: 60-7.
29.	Mercer J, Figg N, Stoneman V, Braganza D, Bennett MR. Endogenous p53 protects vascular smooth muscle cells from apoptosis and reduces atherosclerosis in ApoE knockout mice. Circ Res 2005; 96: 667-74. PMID
30.	Zhang Y, Yang X, Bian F, et al. TNF-α promotes early atherosclerosis by increasing transcytosis of LDL across endothelial cells: crosstalk between NF-κB and PPAR-γ. J Mol Cell Cardiol 2014; 72: 85-94. DOI PMID
31.	Li Z, Wu X, Gu L, et al. Long non-coding RNA ATB promotes malignancy of esophageal squamous cell carcinoma by regulating miR-200b/Kindlin-2 axis. Cell Death Dis 2017; 8: e2888.
32.	Li T, Wang DJ, Xu YY, et al. Metformin regulates macrophage differentiation and inhibits formation of atherosclerosis by activating AMPK/ STAT3 pathway in mice. Zhong Guo Dong Mai Za Zhi 2022; 30: 287-94.
33.	Laubach JP, Fu P, Jiang X, et al. Polycythemia vera erythroid precursors exhibit increased proliferation and apoptosis resistance associated with abnormal RAS and PI3K pathway activation. Exp Hematol 2009; 37: 1411-22. DOI PMID
34.	Wang MM, Xue M, Yang L, et al. Chinese herbal compounds for supplementing Qi and activating blood circulation combined with dual antiplatelet drugs alleviated human umbilical vein endothelial cell injury and platelet adhesion via up-regulation of PI3K/Akt Pathway. Zhong Guo Zhong Xi Yi Jie He Za Zhi 2016; 36: 842-8.
35.	Marx C, Novotny J, Salbeck D, et al. Eosinophil-platelet interactions promote atherosclerosis and stabilize thrombosis with eosinophil extracellular traps. Blood 2019; 134: 1859-72. DOI PMID
36.	Fruman DA, Chiu H, Hopkins BD, Bagrodia S, Cantley LC, Abraham RT. The PI3K pathway in human disease. Cell 2017; 170: 605-35. DOI PMID
37.	Chaperot L, Blum A, Manches O, et al. Virus or TLR agonists induce TRAIL-mediated cytotoxic activity of plasmacytoid dendritic cells. J Immunol 2006; 176: 248-55. DOI PMID
38.	Mukherji A, Janbandhu VC, Kumar V. HBx protein modulates PI3K/Akt pathway to overcome genotoxic stress-induced destabilization of cyclin D1 and arrest of cell cycle. Indian J Biochem Biophys 2009; 46: 37-44.

Target	UniProt ID	Degree Layout	BC	CC	Target	UniProt ID	Degree Layout	BC	CC
AKT1	P31749	282	0.0026	0.45	ALB	P02768	268	0.0033	0.9545
TP53	Q12888	284	0.0045	1.0	EGFR	P00533	260	0.0045	1.0
TNF	P01375	282	0.0045	1.0	STAT3	P40763	258	0.0045	1.0
GAPDH	P04406	278	0.0045	1.0	IL1B	P01584	252	0.0032	0.9545

Target	UniProt ID	Degree Layout	BC	CC	Target	UniProt ID	Degree Layout	BC	CC
AKT1	P31749	282	0.0026	0.45	ALB	P02768	268	0.0033	0.9545
TP53	Q12888	284	0.0045	1.0	EGFR	P00533	260	0.0045	1.0
TNF	P01375	282	0.0045	1.0	STAT3	P40763	258	0.0045	1.0
GAPDH	P04406	278	0.0045	1.0	IL1B	P01584	252	0.0032	0.9545

Mol ID	Molecule name	Degree	BC	CC
MOL000422	Kaempferol	222	0.0063	0.4027
MOL000098	Quercetin	185	0.0043	0.4007
MOL002714	Baicalein	152	0.0058	0.4017
MOL000173	Wogonin	108	0.0032	0.3998
MOL008206	Moslosooflavone	80	0.0029	0.4027
MOL000006	Luteolin	78	0.0029	0.4017
MOL002915	Salvigenin	78	0.0028	0.4017
MOL012266	Rivularin	70	0.0032	0.3950
MOL002719	6-Hydroxynaringenin	52	0.0021	0.3832
MOL012246	5,7,4'-Trihydroxy-8-methoxyflavanone	44	0.0017	0.3808

Mol ID	Molecule name	Degree	BC	CC
MOL000422	Kaempferol	222	0.0063	0.4027
MOL000098	Quercetin	185	0.0043	0.4007
MOL002714	Baicalein	152	0.0058	0.4017
MOL000173	Wogonin	108	0.0032	0.3998
MOL008206	Moslosooflavone	80	0.0029	0.4027
MOL000006	Luteolin	78	0.0029	0.4017
MOL002915	Salvigenin	78	0.0028	0.4017
MOL012266	Rivularin	70	0.0032	0.3950
MOL002719	6-Hydroxynaringenin	52	0.0021	0.3832
MOL012246	5,7,4'-Trihydroxy-8-methoxyflavanone	44	0.0017	0.3808

Target	PDB-ID	Ligand-ID	Resolution	Target	PDB-ID	Ligand-ID	Resolution
AKT1	8PP9	4IM	1.73 ?	EGFR	8A2D	KXY	1.11 ?
TP53	8QZD	XDZ	1.30 ?	STAT3	8XAM	XRH	1.30 ?
TNF	8BRO	R7E	1.55 ?	IL1B	8TWJ	UDP	1.90 ?
GAPDH	8J40	CLM	1.57 ?	PI3K	8XPV	4Z5	1.55 ?
ALB	8BSG	DIF	1.89 ?

Home

Online First

Author Center

Reviewer Center

Issues

Announcement

About Us

Network pharmacology-based analysis of the antithrombotic clinical efficacy and antithrombotic mechanism of Huoxue Jiedu prescription (活血解毒方) in the treatment of polycythemia vera with heat toxin and blood stasis syndrome

RichHTML

PDF

Supplement

Knowledge

Abstract

Cite this article

share this article

Figures/Tables 12

References 38.

Related Articles 15

Recommended Articles

Metrics

Comments

Item		Control (n = 30)	Treatment (n = 30)
n		30	30
Gender (male/female, n)		17/13	19/11
Average age (years)		51±12	51±13
Previous history of thrombosis/bleeding (n)		16	17
ECOG (n)	0	20	18
	1	9	10
	2+	1	2

Group	Degree of dark reddish complexion		Condition of petechiae and ecchymosis		Tongue
Group	Before treatment	After treatment	Before treatment	After treatment	Before treatment	Before treatment
Control (n = 30)	5.20±0.41	3.27±0.26	4.48±0.23	2.31±0.27	2.37±0.29	1.43±0.47
Treatment (n = 30)	5.17±0.38^a	2.53±0.33^ab	4.37±0.26^a	1.31±0.31	2.41±0.32	0.88±0.45

Group	Time	HGB (g/L)	PLT (×10⁹/L)	HCT (%)	WBC (×10⁹/L)
Control (n = 30)	Before treatment	215.8±36.3	251.3±53.8	62.4±11.9	14.4±2.1
Control (n = 30)	After treatment	158.7±28.6^a	190.7±31.3^a	28.1±5.4^a	8.3±1.2^a
Treatment (n = 30)	Before treatment	199.6±26.6	240.7±50.6	58.91±11.00	14.2±2.4
Treatment (n = 30)	After treatment	139.0±22.4^ab	169.5±39.5^ab	25.6±5.7^ab	6.2±1.1^ab

Group	Time	D-D (ng/mL)	APTT (s)	PT (s)	FIB (g/L)
Control (n = 30)	Before treatment	649.50±99.50	42.50±9.50	17.86±2.25	5.07±1.03
Control (n = 30)	After treatment	579.24±81.05^a	36.90±7.38^a	14.74±2.08^a	4.12±1.13^a
Treatment ( n = 30)	Before treatment	639.50±109.50	42.89±8.74	18.25±1.92	5.45±1.39
Treatment ( n = 30)	After treatment	413.59±62.83^ab	31.68±7.07^ab	11.18±2.04^ab	3.42±0.93^ab

Group	Time	PI3K	AKT1
Control (n = 30)	Before treatment	1.002±0.070	1.003±0.081
	After treatment	0.756±0.019^a	0.946±0.026^a
Treatment ( n = 30)	Before treatment	1.007±0.122	1.003±0.076
	After treatment	0.634±0.017^ab	0.762±0.020^ab

[1]	LEI Xiaochun, LIU Cuizhen, LIN Xiujuan, XIE Xiangyu, KE Wei, QIU Zhenwen, TANG Hongmei, HUANG Yushen, ZHANG Lijuan, HUANG Baoyuan, WAN Xin, LI Detang. Effect of improved Yupingfeng powder prescription (玉屏风散加味) on interleukin-33/suppression of tumorigenicity 2 pathway in mice with ovalbumins-induced allergic rhinitis [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1215-1227.
[2]	ZHANG Yuan, CHENG Shizan, HUA Yue, SHI Ji, SU Guoming, ZHANG Chao, LIAN Jing, LIU Pengpeng, JIA Tianzhu. Mechanisms of Suanzaoren (Ziziphi Spinosae Semen) and its processed products in treating insomnia: an integrated study based on network pharmacology and metabolomics [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1307-1316.
[3]	LI Keyao, SHU Ye, CHANG Jing, TANG Jianping, ZHANG Litao, WEI Zhu. Psoriasis intervention by Huai’er (Trametes): unveiling novel targets via network pharmacology [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1317-1329.
[4]	MA Guiping, CHEN Ran, LI Junlong, SUN Le, HU Shiping, ZHANG Yiyi, HONG Chuangxiong. Network pharmacology combined with in vivo experiments to explore the molecular mechanism of Jiawei Erzhi pill (加味二至丸) protects against atherosclerosis by inhibiting ferroptosis [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1330-1341.
[5]	YANG Feng, ZHANG Xuming, WU Zhiyuan, GAO Jiandong. Network pharmacology combined with ultra-high-performance liquid chromatography-quadrupole time-of-flight mass spectrometry method to explore the mechanism of Shizhi Fang (矢志方) in treating uric acid nephropathy mice [J]. Journal of Traditional Chinese Medicine, 2025, 45(6): 1342-1352.
[6]	PEI Ke, LI Yong, LIN Zhe, LYU Guangfu. Mechanisms of Baishao (Radix Paeoniae Alba) and Gancao (Radix Glycyrrhizae) on major depressive disorder: network pharmacology and in vivo validation [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 1067-1077.
[7]	ZHANG Wei, REN Changhong, GAO Chen, XU Jun, WU Xiaodan, YANG Yong. Systematic understanding of mechanism of Shenfu decoction (参附汤) improve the prognosis of ischemic stroke using a network pharmacology and animal experiment approach [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 1078-1086.
[8]	QI Yafeng, LIU Yu, LIU Yeyuan, LI Yangyang, ZHANG Shangzu, CHEN Yaping, XU Qian, HAO Guoxiong, LIU Yongqi, ZHANG Liying, ZHANG Zhiming. Therapeutic potential of Traditional Chinese Medicine Yisui Shengxue pills (益髓生血丸) to inhibit hypoxia-inducible factor-1alpha and general control nonderepressible 2 to regulate the post-chemotherapy immune response: integrating network pharmacology and experimental validation [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 1087-1097.
[9]	CHOI You Yeon, JIN Seong chul, KIM Mi Hye, BAEK Hee Kyung, KIM Dong Hyun, OH Sung Hyuk, YANG Woong Mo. Exploring the therapeutic potential of Morus alba Linne extract in targeting localized adiposity [J]. Journal of Traditional Chinese Medicine, 2025, 45(5): 970-978.
[10]	SONG Mingming, MEN Bo, CHEN Mei, LIU Rui, MO Hongping, ZHANG Da, PAN Tao, WEN Xudong. Exploration of the mechanism of Danggui Buxue decoction (当归补血汤) for the treatment of gastric ulcer based on network pharmacology, molecular docking, and in vivo experiment [J]. Journal of Traditional Chinese Medicine, 2025, 45(4): 806-816.
[11]	LI Yue, DENG Jinyan, PI Shanshan, ZHANG Yingjuan, ZHAO Dan, GUO Yi, YE Yong’an, ZAO Xiaobin, DU Hongbo. Weifuchun (胃复春 ) exerts therapeutic effects on gastric fundic gland polyps by promoting ferroptosis [J]. Journal of Traditional Chinese Medicine, 2025, 45(3): 618-627.
[12]	HUANG Jiaen, LUO Qing, DONG Gengting, PENG Weiwen, HE Jianhong, DAI Weibo. Xiahuo Pingwei San (夏藿平胃散) attenuated intestinal inflammation in dextran sulfate sodium-induced ulcerative colitis mice through inhibiting the receptor for advanced glycation end-products signaling pathway [J]. Journal of Traditional Chinese Medicine, 2025, 45(2): 311-325.
[13]	HAN Shuai, Du Zhikang, WANG Zirui, HUANG Tianfeng, GE Yali, SHI Jianwen, GAO Ju. Network pharmacology approach to unveiling the mechanism of berberine in the amelioration of morphine tolerance [J]. Journal of Traditional Chinese Medicine, 2025, 45(2): 376-384.
[14]	TAN Xiying, GU Ruxin, TAO Jing, ZHANG Yu, SUN RuiQian, YIN Gang, ZHANG Shuo, TANG Decai. Integrating network pharmacology and experimental validation to uncover the synergistic effects of Huangqi (Radix Astragali Mongolici)-Ezhu (Rhizoma Curcumae Phaeocaulis) with 5-fluorouracil in colorectal cancer models [J]. Journal of Traditional Chinese Medicine, 2025, 45(2): 385-398.
[15]	SHI Jinyu, PAN Fuwei, GE Haiya, YANG Zongrui, ZHAN Hongsheng. Mechanism of Qigu capsule (芪骨胶囊) as a treatment for sarcopenia based on network pharmacology and experimental validation [J]. Journal of Traditional Chinese Medicine, 2025, 45(2): 399-407.